Shawn Olsson - Nov 17, 2025 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)

Role
Chief Commercial Officer
Signature
/s/ Daniel R. Chevallard, as Attorney-in-Fact
Stock symbol
LENZ
Transactions as of
Nov 17, 2025
Transactions value $
-$240,222
Form type
4
Date filed
11/19/2025, 07:02 PM
Previous filing
Apr 9, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Olsson Shawn Chief Commercial Officer C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE, SUITE 300, SOLANA BEACH /s/ Daniel R. Chevallard, as Attorney-in-Fact 2025-11-19 0002015796

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LENZ Common Stock Options Exercise $20.8K +10K +211.28% $2.08 14.7K Nov 17, 2025 Direct
transaction LENZ Common Stock Sale -$108K -4.21K -28.59% $25.74 10.5K Nov 17, 2025 Direct F1, F2
transaction LENZ Common Stock Sale -$153K -5.79K -55.01% $26.37 4.73K Nov 17, 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LENZ Stock Option (right to buy) Options Exercise $0 -10K -15.81% $0.00 53.2K Nov 17, 2025 Common Stock 10K $2.08 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on August 12, 2025.
F2 Represents the weighted average share price of an aggregate total of 4,212 shares sold in the price range of $25.12 to $26.11 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 5,788 shares sold in the price range of $26.12 to $26.81 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Shares issued pursuant to the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan (the "2020 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2020 Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean April 26, 2021.